Actym Therapeutics Announces Issuance of US Patents
02 Jun 2025 //
BUSINESSWIRE
Actym Therapeutics Expands Management Team for Product Pipeline
25 Jun 2024 //
PR NEWSWIRE
Actym Gets IND Clearance For Phase 1 Trial Of ACTM-838 In Solid Tumors
30 May 2024 //
PR NEWSWIRE
Actym Therapeutics Appoints Thomas Smart as CEO
24 Apr 2024 //
PR NEWSWIRE
Actym to Present Preclinical Data on Clinical Candidate ACTM-838
03 Nov 2023 //
PR NEWSWIRE
Actym Appoints Steven Vicik as Chief Technical Officer
26 Oct 2023 //
PR NEWSWIRE
Actym Closes $59.5 Million Series A with New $25.5 Million Extension
18 Oct 2023 //
PR NEWSWIRE
Actym Therapeutics Announces Significant Expansion of Senior Leadership
12 May 2022 //
PRNEWSWIRE
Actym Therapeutics and Wacker Biotech Sign Manufacturing Contract
10 Mar 2022 //
CONTRACTPHARMA

Market Place
Sourcing Support